| Autor: |
Oosterwijk C; Department of Internal Medicine, University Hospital Utrecht, The Netherlands., van Hulst KL, Visser CJ, Woutersen RA, Lips CJ, van den Tweel JG, Höppener JW |
| Jazyk: |
angličtina |
| Zdroj: |
International journal of cancer [Int J Cancer] 1997 Aug 07; Vol. 72 (4), pp. 637-41. |
| DOI: |
10.1002/(sici)1097-0215(19970807)72:4<637::aid-ijc15>3.0.co;2-8 |
| Abstrakt: |
Many patients with exocrine pancreatic cancer develop diabetes mellitus due to insulin resistance. This may relate to concurrent over-production of islet amyloid polypeptide (IAPP) by the pancreatic beta cells. We investigated the effects of pancreatic cancer on circulating IAPP and glucose homeostasis in azaserine-treated rats (developing acinar pancreatic tumours) and BOP-treated hamsters (developing ductular pancreatic tumours). Glucose, insulin and IAPP levels in plasma were neither affected in azaserine-only treated rats nor in animals with enhanced carcinogenesis after chronic caerulein treatment. Azaserine-treated rats on a high-fat diet had decreased insulin levels and enhanced IAPP/insulin ratios in plasma, without hyperglycaemia. All BOP-treated hamsters showed pancreatic carcinogenesis at 6 months post-treatment. Supranormal plasma glucose levels in animals on a low-fat diet were the only change observed. After a second 6-month period, subnormal plasma glucose levels, at least 4-fold decreased plasma insulin and up to 2-fold decreased plasma IAPP levels were present in all hamsters. Remarkably, both in azaserine-treated rats on high-fat and in BOP-treated hamsters, decreased insulin levels and elevated IAPP/insulin ratios are not associated with hyperglycaemia. In contrast to humans with pancreatic cancer, IAPP over-production and hyperglycaemia do not develop in rats and hamsters with (pre-)neoplastic pancreatic lesions. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Plný text